Levadex FDA Approval Status
Levadex (dihydroergotamine) is an investigational orally inhaled ergot alkaloid intended for use in the treatment of migraine.
In April 2013, Allergan, Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for Levadex had not been approved.
Development Timeline for Levadex
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.